A Phase 3 interventional study of Bilastine and Levocetirizine in Urticaria, sponsored by Faes Farma, S.A.. Completed at 50 sites in 7 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2012-04-05.
Sponsored by Faes Farma, S.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of the study is to evaluate the efficacy and tolerability of Bilastine 20 mg Q.D., compared to Levocetirizine 5 mg Q.D. and placebo for the treatment of Chronic Idiopathic Urticaria.
A total of 540 patients with CIU will be enrolled in this pivotal, randomised, multicentre, international, double-blind, placebo and active-comparator controlled, parallel study . Patients will be selected from both public and private clinical practices. The study population includes males and females between 18 and 70 years of age, suffering from CIU for at least 6 weeks prior to entry in the study with no identifiable cause.
148 studies on the registry are indexed under Urticaria; 20 are open to participants now.
This study's enrollment of 522 is above the median of 51 across 104 interventional studies indexed under Urticaria.
Browse Urticaria studies →Faes Farma, S.A. is the lead sponsor of 17 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilastine 20 mg
Drug: Bilastine
Levocetirizine 5 mg
Drug: Levocetirizine
Placebo
Drug: Placebo
Encapsulated 20 mg Tablet. Once daily for 28 days
Encapsulated 5 mg tablet. Once daily for 28 days
Also known as: Xyzall
Encapsulated tablet. Once daily for 28 days
Change from baseline, in the am/pm Total Symptom Score (TSS3), over the 28 days of the treatment period according to the patient's assessment in the diary card. (Reflective Symptoms)
Time frame: 28 days
Reflective and Instantaneous symptoms scores.
Time frame: 28 days
QoL questionnaire.
Time frame: 28 days
Overall assessment of discomfort caused by CIU.
Time frame: 28 days
Investigator's overall clinical impression.
Time frame: End of study
Assessment of the Impact of urticaria on the sleep scale.
Time frame: 28 days
The record gives a start of Jul 2006, a primary completion of Jul 2007 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bilastine
Faes Farma, S.A.